Brief: Coya Therapeutics Announces Results Of Investigator-Initiated Study Of Ld Il-2 And Ctla4-Ig
08/01/2026 13:39
Jan 8 (Reuters) - Coya Therapeutics Inc COYA.O: COYA THERAPEUTICS ANNOUNCES RESULTS OF INVESTIGATOR-INITIATED STUDY OF LD IL-2 AND CTLA4-IG DEMONSTRATING TREG ENHANCEMENT AND COGNITIVE STABILITY IN FRONTOTEMPORAL DEMENTIA PATIENTS Source text: ID:nBwFB3b6a Further company coverage: COYA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)